Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 9/2018

01-09-2018 | Original Article

Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015)

Authors: Giulia De Angelis, Barbara Fiori, Giulia Menchinelli, Tiziana D’Inzeo, Flora Marzia Liotti, Grazia Angela Morandotti, Maurizio Sanguinetti, Brunella Posteraro, Teresa Spanu

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 9/2018

Login to get access

Abstract

The proportion of antimicrobial resistance (AMR) among the ESKAPE and Escherichia coli (ESKAPEEc) pathogens causing bloodstream infection (BSI) increased worldwide. We described longitudinal trends in ESKAPEEc BSI and AMR over 9 years (2007–2015) at a large teaching hospital in Italy. Of 9720 unique BSI episodes, 6002 (61.7%) were caused by ESKAPEEc pathogens. The majority of these episodes (4374; 72.9%) were hospital-onset infections. The most frequent pathogen was E. coli (32.8%), followed by Staphylococcus aureus (20.6%), Klebsiella pneumoniae (16.1%), and Pseudomonas aeruginosa (11.6%). There was a significant increase of hospital-onset K. pneumoniae (from 2.3 to 5.0 per 10,000 patient-days; P = 0.001) and community-onset E. coli (from 3.3 to 9. 1 per 10,000 emergency admissions; P = 0.04) BSIs. Among hospital-onset BSIs, increases of extended-spectrum β-lactamase (ESBL)-producing E. coli (from 25.4 to 35.2%, P = 0.006), carbapenemase-producing K. pneumoniae (from 4.2 to 51.6%, P < 0.001), and methicillin-resistant S. aureus (from 33.9 to 44.4%, P < 0.001) BSIs were observed between the 2007–2009 and 2010–2012 study periods. In contrast, a decrease of BSIs caused by P. aeruginosa resistant to ceftazidime (from 45.5 to 28.2%, P < 0.001), ciprofloxacin (from 46 to 36.3%, P = 0.05), and meropenem (from 55 to 39.9%, P = 0.03) was observed through all 9 years of the study period. Among community-onset BSIs, increases of BSIs caused by ESBL-producing E. coli (from 28.6 to 42.2%, P = 0.002) and carbapenemase-producing K. pneumoniae (from 0 to 17.6%) were observed between the 2007–2009 and 2010–2012 study periods. Our findings show increased rates of BSI and relative AMR for specific pathogen-health care setting combinations, and call for continued active surveillance and infection control policies.
Appendix
Available only for authorised users
Literature
7.
go back to reference Zhang H, Yang Q, Liao K, Ni Y, Yu Y, Hu B, Sun Z, Huang W, Wang Y, Wu A, Feng X, Luo Y, Hu Z, Chu Y, Chen S, Cao B, Su J, Gui B, Duan Q, Zhang S, Shao H, Kong H, Badal RE, Xu Y (2015) Antimicrobial susceptibilities of aerobic and facultative Gram-negative bacilli from intra-abdominal iInfections in patients from seven regions in China in 2012 and 2013. Antimicrob Agents Chemother 60:245–251. https://doi.org/10.1128/AAC.00956-15 CrossRefPubMedPubMedCentral Zhang H, Yang Q, Liao K, Ni Y, Yu Y, Hu B, Sun Z, Huang W, Wang Y, Wu A, Feng X, Luo Y, Hu Z, Chu Y, Chen S, Cao B, Su J, Gui B, Duan Q, Zhang S, Shao H, Kong H, Badal RE, Xu Y (2015) Antimicrobial susceptibilities of aerobic and facultative Gram-negative bacilli from intra-abdominal iInfections in patients from seven regions in China in 2012 and 2013. Antimicrob Agents Chemother 60:245–251. https://​doi.​org/​10.​1128/​AAC.​00956-15 CrossRefPubMedPubMedCentral
10.
go back to reference World Health Organization (2017) Global Priority List of Antibiotic-Resistance Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Home page at: http://www.who.int. Accessed 4 January 2018 World Health Organization (2017) Global Priority List of Antibiotic-Resistance Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Home page at: http://​www.​who.​int. Accessed 4 January 2018
12.
go back to reference Giani T, Antonelli A, Caltagirone M, Mauri C, Nicchi J, Arena F, Nucleo E, Bracco S, Pantosti A; AMCLI-CoSA survey participants, Luzzaro F, Pagani L, Rossolini GM (2017) Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Euro Surveill 22(31): DOI: https://doi.org/10.2807/1560-7917 Giani T, Antonelli A, Caltagirone M, Mauri C, Nicchi J, Arena F, Nucleo E, Bracco S, Pantosti A; AMCLI-CoSA survey participants, Luzzaro F, Pagani L, Rossolini GM (2017) Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Euro Surveill 22(31): DOI: https://​doi.​org/​10.​2807/​1560-7917
14.
go back to reference European Centre for Disease Prevention and Control (2017) Surveillance of antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Home page at: https://ecdc.europa.eu/. Accessed 04 January 2018 European Centre for Disease Prevention and Control (2017) Surveillance of antimicrobial resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Home page at: https://​ecdc.​europa.​eu/​. Accessed 04 January 2018
15.
go back to reference European Centre for Disease Prevention and Control (2016) Summary of the latest data on antibiotic resistance in the European Union. Home page at: https://ecdc.europa.eu/. Accessed 04 January 2018 European Centre for Disease Prevention and Control (2016) Summary of the latest data on antibiotic resistance in the European Union. Home page at: https://​ecdc.​europa.​eu/​. Accessed 04 January 2018
16.
go back to reference Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gür D, Jarlier V, Kahlmeter G, Monen J, Monnet DL, Rossolini GM, Suetens C, Weist K, Heuer O; EARS-Net Participants (Disease Specific Contact Points for AMR) (2011) Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 16(11):pii=19819. https://doi.org/10.2807/ese.16.11.19819-en Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gür D, Jarlier V, Kahlmeter G, Monen J, Monnet DL, Rossolini GM, Suetens C, Weist K, Heuer O; EARS-Net Participants (Disease Specific Contact Points for AMR) (2011) Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 16(11):pii=19819. https://​doi.​org/​10.​2807/​ese.​16.​11.​19819-en
17.
go back to reference Schlackow I, Stoesser N, Walker AS, Crook DW, Peto TE, Wyllie DH, Infections in Oxfordshire Research Database Team (2012) Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999–2011. J Antimicrob Chemother 67:1514–1524. https://doi.org/10.1093/jac/dks082 CrossRefPubMed Schlackow I, Stoesser N, Walker AS, Crook DW, Peto TE, Wyllie DH, Infections in Oxfordshire Research Database Team (2012) Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999–2011. J Antimicrob Chemother 67:1514–1524. https://​doi.​org/​10.​1093/​jac/​dks082 CrossRefPubMed
18.
go back to reference Arnaud I, Maugat S, Jarlier V, Astagneau P; National Early Warning, Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)/multidrug resistance study group (2015) Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. Euro Surveill 20(36):pii=30014. https://doi.org/10.2807/1560-7917 Arnaud I, Maugat S, Jarlier V, Astagneau P; National Early Warning, Investigation and Surveillance of Healthcare-Associated Infections Network (RAISIN)/multidrug resistance study group (2015) Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013. Euro Surveill 20(36):pii=30014. https://​doi.​org/​10.​2807/​1560-7917
21.
23.
go back to reference Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994. https://doi.org/10.1128/AAC.01509-06 CrossRefPubMedPubMedCentral Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:1987–1994. https://​doi.​org/​10.​1128/​AAC.​01509-06 CrossRefPubMedPubMedCentral
24.
go back to reference Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D'Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T (2008) Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52:3244–3252. https://doi.org/10.1128/AAC.00063-08 CrossRefPubMedPubMedCentral Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, De Pascale G, D'Inzeo T, Sanguinetti M, Fadda G, Cauda R, Spanu T (2008) Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52:3244–3252. https://​doi.​org/​10.​1128/​AAC.​00063-08 CrossRefPubMedPubMedCentral
26.
go back to reference Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing Kp: importance of combination therapy. Clin Infect Dis 55:943–950. https://doi.org/10.1093/cid/cis588 CrossRefPubMed Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing Kp: importance of combination therapy. Clin Infect Dis 55:943–950. https://​doi.​org/​10.​1093/​cid/​cis588 CrossRefPubMed
27.
go back to reference Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva) (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143. https://doi.org/10.1093/jac/dkv086 CrossRefPubMed Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva) (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133–2143. https://​doi.​org/​10.​1093/​jac/​dkv086 CrossRefPubMed
29.
go back to reference European Committee on Antimicrobial Susceptibility Testing (2018) Breakpoint tables for interpretation of MICs and zone diameters. Version 8. 0. Home page at: http://www.eucast.org. Accessed 8 January 2018 European Committee on Antimicrobial Susceptibility Testing (2018) Breakpoint tables for interpretation of MICs and zone diameters. Version 8. 0. Home page at: http://​www.​eucast.​org. Accessed 8 January 2018
30.
go back to reference European Committee on Antimicrobial Susceptibility Testing (2017) EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0. 0 . Home page at: http://www.eucast.org . Accessed 20 May 2017 European Committee on Antimicrobial Susceptibility Testing (2017) EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0. 0 . Home page at: http://​www.​eucast.​org . Accessed 20 May 2017
31.
go back to reference Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570 CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://​doi.​org/​10.​1111/​j.​1469-0691.​2011.​03570 CrossRefPubMed
34.
go back to reference Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ (2018) Towards precision medicine in Sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.03.011 Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ (2018) Towards precision medicine in Sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. https://​doi.​org/​10.​1016/​j.​cmi.​2018.​03.​011
Metadata
Title
Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015)
Authors
Giulia De Angelis
Barbara Fiori
Giulia Menchinelli
Tiziana D’Inzeo
Flora Marzia Liotti
Grazia Angela Morandotti
Maurizio Sanguinetti
Brunella Posteraro
Teresa Spanu
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 9/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3292-9

Other articles of this Issue 9/2018

European Journal of Clinical Microbiology & Infectious Diseases 9/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.